How would you approach adjuvant therapy in a patient with HR+ breast cancer with a high RS (>25) given the current COVID-19 pandemic?

Topics: Breast Cancer • Medical Oncology • HR+ • COVID-19

Would you consider delaying chemotherapy and proceeding only with endocrine for now?

Answer from: Medical Oncologist at Academic Institution

The starting point for consideration of adjuvant chemotherapy is to quantify the risk of a distant recurrence. For estrogen receptor positive, HER2 negative breast cancer, Oncotype Dx RS data are critical for understanding the risk of a distant recurrence1 as well as endocrine and chemotherapy respo...

Comments

Medical Oncologist at Lehigh Valley Physicians Group
Can we start with ET in these cases and do adjuvan...

Medical Oncologist at Hennepin County Medical Center
I have also been wondering whether it makes a diff...

Medical Oncologist at Mayo Clinic
I agree completely. This clearly must be taken int...

Answer from: Medical Oncologist at Academic Institution

In the face of the COVID-19 pandemic and the increased mortality of elderly patients with COVID-19, the potential benefit of adjuvant chemotherapy in elderly individuals with ER pos HER2 neg needs to be carefully weighed against the potentially increased risk of complications. I think one could dela...

Related Questions